GRAIL, Inc. (GRAL)
Healthcare • Diagnostics & Research
StockNasdaqGSUnited StatesUS3847471014
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by GRAIL, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 14:05. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 18 Feb 2027 16:00 | -1.51 | — | — | Upcoming |
| 04 Nov 2026 16:00 | -1.90 | 3.00 | +257.9% | Beat |
| 05 Aug 2026 16:00 | -2.43 | -1.34 | +44.9% | Beat |
| 05 May 2026 16:00 | -1.96 | -1.37 | +30.1% | Beat |
| 19 Feb 2026 16:00 | -2.53 | -2.44 | +3.6% | Beat |
| 12 Nov 2025 16:00 | -3.26 | -2.46 | +24.7% | Beat |
| 12 Aug 2025 16:00 | -3.56 | -3.18 | +10.8% | Beat |
| 13 May 2025 16:00 | -3.80 | -3.10 | +18.5% | Beat |
| 20 Feb 2025 16:00 | -4.97 | -2.89 | +41.9% | Beat |
| 12 Nov 2024 16:00 | -6.43 | -3.50 | +45.5% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 147.2M | +17.2% | -408.4M | -277.5% | -11.11 | +82.5% | -299.9M |
| 2024 | 125.6M | +34.9% | -2B | -1,613.9% | -63.54 | -34.6% | -582.4M |
| 2023 | 93.1M | +67.6% | -1.5B | -1,574.2% | -47.21 | +72.9% | -608.7M |
| 2022 | 55.6M | — | -5.4B | -9,719.3% | -173.89 | — | -584.2M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 120.50 | 122.68 | 115.28 | 121.35 | -3.41% | 596,600 | |
| 11 Nov 2026 | 130.45 | 133.00 | 124.83 | 125.64 | +0.72% | 513,400 | |
| 10 Nov 2026 | 125.88 | 127.70 | 120.41 | 124.74 | -2.61% | 667,600 | |
| 09 Nov 2026 | 123.63 | 134.26 | 122.36 | 128.08 | +5.47% | 809,400 | |
| 06 Nov 2026 | 122.00 | 129.70 | 117.00 | 121.44 | +1.94% | 756,000 | |
| 05 Nov 2026 | 119.50 | 130.00 | 117.21 | 119.13 | -17.08% | 2,095,000 | |
| 04 Nov 2026 | 140.30 | 143.82 | 132.02 | 143.66 | +3.03% | 757,000 | |
| 03 Nov 2026 | 136.97 | 144.23 | 136.66 | 139.44 | +4.25% | 1,272,400 | |
| 02 Nov 2026 | 148.53 | 149.00 | 132.13 | 133.76 | -6.74% | 983,200 | |
| 30 Oct 2026 | 152.08 | 155.18 | 141.00 | 143.43 | -9.75% | 1,072,400 | |
| 598 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Got $10,000? 3 Hot Stocks to Buy That Could Make You a Fortune (opens in a new tab) Motley Fool · 10 Nov 2026 21:50
- GRAIL, Inc. (GRAL) Presents at 2026 UBS Global Healthcare Conference Transcript (opens in a new tab) SeekingAlpha · 10 Nov 2026 13:31
- Grail Exec Says Co. In Conversations With Commercial Payers For Galleri Cancer Test (opens in a new tab) Benzinga · 10 Nov 2026 12:20
- Grail Exec Expects FDA Decision On Approval For Galleri Cancer Test By Early Q1 2027; Expects Galleri Cancer Test To Be Reimbursed At $500 To $600 (opens in a new tab) Benzinga · 10 Nov 2026 12:17
- GRAIL Exec Expects Broad Label For Galleri Cancer Test Based On Data Co Has Submitted To FDA (opens in a new tab) Benzinga · 10 Nov 2026 12:14
- Piper Sandler Maintains Neutral on GRAIL, Raises Price Target to $130 (opens in a new tab) Benzinga · 10 Nov 2026 08:56
- GRAIL Inc (GRAL) (Q3 2026) Earnings Call Highlights: FDA Nod on the Horizon as Galleri Gains ... (opens in a new tab) GuruFocus.com · 10 Nov 2026 01:05
- A Bloody Bad Time: Grail Gutted On Light Blood Test Sales (opens in a new tab) Investor's Business Daily · 05 Nov 2026 21:16
- Is GRAIL (GRAL) Fully Valued As Fresh Earnings Reignite Questions Over Galleri? (opens in a new tab) Simply Wall St. · 05 Nov 2026 16:16
- GRAIL (GRAL) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 15:58
- RBC Capital Maintains Sector Perform on GRAIL, Raises Price Target to $100 (opens in a new tab) Benzinga · 05 Nov 2026 15:27
- GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth (opens in a new tab) Zacks · 05 Nov 2026 14:00
- GRAIL, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 05 Nov 2026 13:30
- What GRAIL (GRAL) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 05 Nov 2026 01:14
- GRAIL (NASDAQ:GRAL) Slides After Q3 Revenue Miss Despite Narrower Loss (opens in a new tab) ChartMill · 04 Nov 2026 23:25
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 125.64 USD
- Market cap
- 5.5B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow GRAL and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.